Discover what Novelmab is, how its dual targeting of PD‑1 and a tumor‑associated antigen works, and why this next‑generation bispecific antibody is generating buzz in oncology for potentially overcoming resistance to standard immunotherapy in solid tumors.
- admin@condrug.com
- Mon - Sat: 8.00 am - 7.00 pm
We develop solutions for your clinical data needs